Nan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nan Zhang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Hong Xu
Department of Gastroenterology, The First Hospital of Jilin University
8 shared publications Huimei Wang
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
7 shared publicationsMingqing Liu
Department of Gastroenterology and Endoscopy Center, The First Hospital of Jilin University, No.71 Xinmin Street, Changchun, Jilin Province 130021, China
7 shared publicationsYingli Zhang
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
7 shared publicationsLuping Zhang
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
6 shared publicationsWeidan Zhao
Department of Gastroenterology, The First Hospital of Jilin University, ChangChun, China
6 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer
Emerging evidence implicates insomnia as a potential risk factor in carcinogenesis, potentially involving systemic inflammation, circadian disruption, and microbiome alterations. However, the molecular associations linking insomnia-related features to colorectal cancer (CRC), particularly with respect to tumor biology, immune microenvironmental states, and therapy-relevant phenotypes, remain largely unexplored. Multi-omics integration of genomic, transcriptomic, and microbiome data from 3,026 CRC patients across seven independent cohorts, including a large, well-annotated Clinical Omics study of Colorectal Cancer in China (COCC) cohort, enabled insomnia-based molecular classification through unsupervised non-negative matrix factorization (NMF) clustering. The insomnia subtype (IS) was biologically characterized via pathway enrichment, immune deconvolution, microbial profiling, and single-cell transcriptomics. Furthermore, an insomnia score (ISscore) was developed and validated in multiple cohorts for risk stratification and assessment of treatment-response-related indicators in CRC. Unsupervised clustering revealed two distinct molecular subtypes (IS1/IS2), with IS2 demonstrating significantly poorer survival. IS2 exhibited marked activation of EMT/angiogenesis pathways versus cell cycle activation in IS1. The IS2 microenvironment showed increased immunosuppression-related infiltration and exhausted T cell signatures, together with intratumoral microbiome variation characterized by depletion of Ruminococcaceae UCG-002 and enrichment of Hungatella/Selenomonas. The ISscore system stratified survival risk and was associated with computational indicators of immunotherapy response. Single-cell analysis nominated PPIA-BSG as a potential cell-cell communication signal involving high-ISscore tumor cells, CXCL12+ endothelial cells, and CLEC9A+ dendritic cell subsets. This multi-omics characterization of insomnia-CRC interplay suggests that insomnia-related molecular features are associated with an immunologically distinct and microbiome-altered tumor ecosystem. The ISscore provides a reproducible framework for capturing insomnia-related molecular heterogeneity, supporting risk stratification and future evaluation of therapy-relevant phenotypes. IMPORTANCE: Chronic insomnia affects millions, but it is not typically considered a cancer risk factor. Our study, analyzing vast biological data from over 3,000 colorectal cancer patients, uncovers a potential link between a person’s predisposition to insomnia and their risk of developing this disease. This suggests that the biological pathways related to sleep may play a role in cancer development. Understanding this connection opens up new avenues for identifying individuals at higher risk and developing novel prevention strategies for colorectal cancer.
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (10)
Open AccessIntegrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer
Emerging evidence implicates insomnia as a potential risk factor in carcinogenesis, potentially involving systemic inflammation, circadian disruption, and microbiome alterations. However, the molecular associations linking insomnia-related features to colorectal cancer (CRC), particularly with respect to tumor biology, immune microenvironmental states, and therapy-relevant phenotypes, remain largely unexplored. Multi-omics integration of genomic, transcriptomic, and microbiome data from 3,026 CRC patients across seven independent cohorts, including a large, well-annotated Clinical Omics study of Colorectal Cancer in China (COCC) cohort, enabled insomnia-based molecular classification through unsupervised non-negative matrix factorization (NMF) clustering. The insomnia subtype (IS) was biologically characterized via pathway enrichment, immune deconvolution, microbial profiling, and single-cell transcriptomics. Furthermore, an insomnia score (ISscore) was developed and validated in multiple cohorts for risk stratification and assessment of treatment-response-related indicators in CRC. Unsupervised clustering revealed two distinct molecular subtypes (IS1/IS2), with IS2 demonstrating significantly poorer survival. IS2 exhibited marked activation of EMT/angiogenesis pathways versus cell cycle activation in IS1. The IS2 microenvironment showed increased immunosuppression-related infiltration and exhausted T cell signatures, together with intratumoral microbiome variation characterized by depletion of Ruminococcaceae UCG-002 and enrichment of Hungatella/Selenomonas. The ISscore system stratified survival risk and was associated with computational indicators of immunotherapy response. Single-cell analysis nominated PPIA-BSG as a potential cell-cell communication signal involving high-ISscore tumor cells, CXCL12+ endothelial cells, and CLEC9A+ dendritic cell subsets. This multi-omics characterization of insomnia-CRC interplay suggests that insomnia-related molecular features are associated with an immunologically distinct and microbiome-altered tumor ecosystem. The ISscore provides a reproducible framework for capturing insomnia-related molecular heterogeneity, supporting risk stratification and future evaluation of therapy-relevant phenotypes. IMPORTANCE: Chronic insomnia affects millions, but it is not typically considered a cancer risk factor. Our study, analyzing vast biological data from over 3,000 colorectal cancer patients, uncovers a potential link between a person’s predisposition to insomnia and their risk of developing this disease. This suggests that the biological pathways related to sleep may play a role in cancer development. Understanding this connection opens up new avenues for identifying individuals at higher risk and developing novel prevention strategies for colorectal cancer.
- Open Access
- 10 January 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 399, 121176
Bidirectional, time-ordered association network linking psychiatric disorders and immune-mediated inflammatory diseases: Inflammation–sleep mediation and genetic modification
- 10 January 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 399, 121176
Open AccessBidirectional, time-ordered association network linking psychiatric disorders and immune-mediated inflammatory diseases: Inflammation–sleep mediation and genetic modification
- Open Access
- 23 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (2) , 286
Authors’ reply: Comment on “comparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions”
- 23 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (2) , 286
Open AccessAuthors’ reply: Comment on “comparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions”
- Open Access
- 26 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
From biomarker to clinical utility: translating the advanced lung cancer inflammation index into a machine learning-driven risk stratification tool for colorectal cancer
Background: Both nutrition and inflammation have been implicated in the pathogenesis of colorectal cancer (CRC), but most previous studies have examined these factors separately. This study aimed to explore the combined association of inflammation and nutritional status with CRC. Methods: This study selected 101,316 subjects from the National Health and Nutrition Survey (NHANES) conducted from 1999 to 2018. First, weighted logistic regression was used to measure the association between the advanced lung cancer inflammation index (ALI) and CRC. Then, restricted cubic splines (RCS) were used to capture the dose-response curve, and the predictive power of the model was calibrated by the ROC curve. Subsequently, robustness was verified through subgroup and interaction analyses. Furthermore, random forest analysis combined with the Boruta algorithm was employed to identify CRC-related factors. Subsequently, a machine learning(ML) prediction framework is constructed, and the black box of the optimal model is disassembled using SHAP values to endow it with interpretability. Results: In the fully adjusted model, each unit increase in log-transformed ALI was associated with a 20.9% reduction in CRC risk (OR = 0.791; 95% CI: 0.628–0.997; p = 0.047). Participants in the highest log-ALI quartile had a 46.2% lower risk compared to those in the lowest quartile (OR = 0.538; 95% CI: 0.344–0.842; P = 0.007). The fully adjusted model demonstrated strong discriminative ability (AUC = 0.848). RCS analysis confirmed a linear dose-response relationship (P for nonlinearity = 0.731). The robustness of these findings was supported by subgroup and sensitivity analyses. Random forest analysis coupled with the Boruta algorithm identified log-ALI as a strong predictor. Among seven machine learning models evaluated, the LightGBM algorithm achieved the highest and most stable predictive performance (AUC = 0.870). SHAP analysis confirmed log-ALI as the most important protective feature. Conclusion: This study demonstrates that higher ALI levels, indicative of better nutritional and inflammatory status, are significantly associated with a lower risk of CRC. The optimized ML model based on ALI shows promise as a cost-effective tool for CRC risk stratification.
- 26 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessFrom biomarker to clinical utility: translating the advanced lung cancer inflammation index into a machine learning-driven risk stratification tool for colorectal cancer
Background: Both nutrition and inflammation have been implicated in the pathogenesis of colorectal cancer (CRC), but most previous studies have examined these factors separately. This study aimed to explore the combined association of inflammation and nutritional status with CRC. Methods: This study selected 101,316 subjects from the National Health and Nutrition Survey (NHANES) conducted from 1999 to 2018. First, weighted logistic regression was used to measure the association between the advanced lung cancer inflammation index (ALI) and CRC. Then, restricted cubic splines (RCS) were used to capture the dose-response curve, and the predictive power of the model was calibrated by the ROC curve. Subsequently, robustness was verified through subgroup and interaction analyses. Furthermore, random forest analysis combined with the Boruta algorithm was employed to identify CRC-related factors. Subsequently, a machine learning(ML) prediction framework is constructed, and the black box of the optimal model is disassembled using SHAP values to endow it with interpretability. Results: In the fully adjusted model, each unit increase in log-transformed ALI was associated with a 20.9% reduction in CRC risk (OR = 0.791; 95% CI: 0.628–0.997; p = 0.047). Participants in the highest log-ALI quartile had a 46.2% lower risk compared to those in the lowest quartile (OR = 0.538; 95% CI: 0.344–0.842; P = 0.007). The fully adjusted model demonstrated strong discriminative ability (AUC = 0.848). RCS analysis confirmed a linear dose-response relationship (P for nonlinearity = 0.731). The robustness of these findings was supported by subgroup and sensitivity analyses. Random forest analysis coupled with the Boruta algorithm identified log-ALI as a strong predictor. Among seven machine learning models evaluated, the LightGBM algorithm achieved the highest and most stable predictive performance (AUC = 0.870). SHAP analysis confirmed log-ALI as the most important protective feature. Conclusion: This study demonstrates that higher ALI levels, indicative of better nutritional and inflammatory status, are significantly associated with a lower risk of CRC. The optimized ML model based on ALI shows promise as a cost-effective tool for CRC risk stratification.
- Open Access
- 24 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Development of deep learning-based narrow-band imaging endocytoscopic classification for predicting colorectal lesions from a retrospective study
Data-driven approaches have advanced colorectal lesion diagnosis in digestive endoscopy, yet their application in endocytoscopy (EC)—a high-magnification imaging technique—remains limited, with most studies relying on conventional machine learning methods like support vector machines. Inspired by the success of large-scale language models that leverage progressive pre-training, we develop a computer-aided diagnosis (CAD) model using narrow-band imaging endocytoscopy (EC-NBI) to classify colorectal lesions (non-neoplastic lesions, adenomas, and invasive cancers). Here, we show that our model, trained through a multi-stage pre-training strategy combined with supervised deep clustering, outperforms state-of-the-art supervised methods in a multi-center retrospective cohort. Notably, it surpasses endoscopists’ diagnostic accuracy in human-machine competitions and enhances their performance when used as an assistive tool. This EC-NBI CAD model significantly improves the accuracy and consistency of diagnosing colorectal lesions, laying a foundation for future early cancer screening, particularly for distinguishing superficial and deep submucosal invasive cancers, pending further expansive multi-center data.
- 24 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessDevelopment of deep learning-based narrow-band imaging endocytoscopic classification for predicting colorectal lesions from a retrospective study
Data-driven approaches have advanced colorectal lesion diagnosis in digestive endoscopy, yet their application in endocytoscopy (EC)—a high-magnification imaging technique—remains limited, with most studies relying on conventional machine learning methods like support vector machines. Inspired by the success of large-scale language models that leverage progressive pre-training, we develop a computer-aided diagnosis (CAD) model using narrow-band imaging endocytoscopy (EC-NBI) to classify colorectal lesions (non-neoplastic lesions, adenomas, and invasive cancers). Here, we show that our model, trained through a multi-stage pre-training strategy combined with supervised deep clustering, outperforms state-of-the-art supervised methods in a multi-center retrospective cohort. Notably, it surpasses endoscopists’ diagnostic accuracy in human-machine competitions and enhances their performance when used as an assistive tool. This EC-NBI CAD model significantly improves the accuracy and consistency of diagnosing colorectal lesions, laying a foundation for future early cancer screening, particularly for distinguishing superficial and deep submucosal invasive cancers, pending further expansive multi-center data.
- Open Access
- 26 August 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (11) , 2114-2120
Comparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions
- 26 August 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (11) , 2114-2120
Open AccessComparison of the diagnostic performance of narrow-band imaging endocytoscopy and staining-based endocytoscopy for colorectal lesions
- Open Access
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1662503
Curative endoscopic resection of giant esophageal dedifferentiated liposarcoma: a case report and literature review
Esophageal dedifferentiated liposarcoma (DDLPS) is extremely rare. We report a case of esophageal dedifferentiated liposarcoma (DDLPS) measuring 12.5 × 3.0 × 2.8 cm in a 62-year-old male presenting with a one-year history of progressive dysphagia. Esophagogastroduodenoscopy and computed tomography showed a large pedunculated submucosal tumor arising from the esophageal entrance and extending intraluminally to 35 cm from the incisor teeth, partially obstructing the esophageal lumen. Curative endoscopic resection was successfully achieved using a novel technique employing an externally placed snare and nylon loop outside the endoscope, thereby avoiding traumatic surgical operation. Histopathologic examination showed that the giant tumor was composed of a differentiated lipomatous component adjacent to dedifferentiated spindle cells. Immunohistochemical analysis revealed spindle cells were positive for p16, CDK4, MDM2, CD34, and CD31. The differentiated lipomatous areas were positive for S-100. The definitive pathologic diagnosis confirmed a dedifferentiated liposarcoma, and the margin was negative. This represents the fifth reported case of esophageal DDLPS successfully managed through endoscopic resection. This externally deployed snare and nylon loop technique provides a viable and less invasive alternative for endoscopic resection of large pedunculated esophageal DDLPS. However, long-term follow-up is necessary to evaluate both therapeutic outcomes and prognosis fully.
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1662503
Open AccessCurative endoscopic resection of giant esophageal dedifferentiated liposarcoma: a case report and literature review
Esophageal dedifferentiated liposarcoma (DDLPS) is extremely rare. We report a case of esophageal dedifferentiated liposarcoma (DDLPS) measuring 12.5 × 3.0 × 2.8 cm in a 62-year-old male presenting with a one-year history of progressive dysphagia. Esophagogastroduodenoscopy and computed tomography showed a large pedunculated submucosal tumor arising from the esophageal entrance and extending intraluminally to 35 cm from the incisor teeth, partially obstructing the esophageal lumen. Curative endoscopic resection was successfully achieved using a novel technique employing an externally placed snare and nylon loop outside the endoscope, thereby avoiding traumatic surgical operation. Histopathologic examination showed that the giant tumor was composed of a differentiated lipomatous component adjacent to dedifferentiated spindle cells. Immunohistochemical analysis revealed spindle cells were positive for p16, CDK4, MDM2, CD34, and CD31. The differentiated lipomatous areas were positive for S-100. The definitive pathologic diagnosis confirmed a dedifferentiated liposarcoma, and the margin was negative. This represents the fifth reported case of esophageal DDLPS successfully managed through endoscopic resection. This externally deployed snare and nylon loop technique provides a viable and less invasive alternative for endoscopic resection of large pedunculated esophageal DDLPS. However, long-term follow-up is necessary to evaluate both therapeutic outcomes and prognosis fully.
- Open Access
- 17 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-19
Development and validation of a disulfidptosis-related prognostic model for colorectal cancer using multi-omics analysis
This study aims to integrate multi-omic and clinical data concerning disulfidptosis-related genes (DRGs) to facilitate molecular typing and prognosis in colorectal cancer (CRC). Public databases provided CRC transcriptome and clinical data, enabling differential expression, genomic analyses, pathway enrichment, survival analysis, and subtyping based on the expression levels of 15 DRGs identified in published studies. Differentially expressed genes (DEGs) between subtypes were identified to create a disulfidptosis prognostic model using LASSO and Cox regression analyses. This model was evaluated by comparing risk scores, survival curves, cellular infiltration, and drug sensitivity between high- and low-risk groups. Analyses revealed differential expression, mutations, and copy number variations (CNV) in DRGs in CRC. Survival analysis demonstrated significant prognostic differences among DRG expression subtypes. GSVA and ssGSEA highlighted DRGs' regulatory roles in CRC. DEGs identified between DRG expression subtypes led to the classification into subtypes A and B. A disulfidptosis prognostic model, including genes VSIG4, SCG2, INHBB, DDC, CXCL13, KLK10, CXCL10, and CCL11A, was developed to stratify patients into high- and low-risk groups. This model displayed strong predictive capability (AUC = 0.700) and calibration. The risk score was also strongly associated with immune cell infiltration, stromal cell score, and stem cell index in the CRC tumor microenvironment. Drug sensitivity analysis indicated that high-risk samples were more responsive to most medications. We established a robust disulfidptosis prognostic model for CRC through comprehensive multi-omics analysis. Our findings provide valuable insights into the role of DRGs in CRC progression and disease management, presenting an important resource for further research.
- 17 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-19
Open AccessDevelopment and validation of a disulfidptosis-related prognostic model for colorectal cancer using multi-omics analysis
This study aims to integrate multi-omic and clinical data concerning disulfidptosis-related genes (DRGs) to facilitate molecular typing and prognosis in colorectal cancer (CRC). Public databases provided CRC transcriptome and clinical data, enabling differential expression, genomic analyses, pathway enrichment, survival analysis, and subtyping based on the expression levels of 15 DRGs identified in published studies. Differentially expressed genes (DEGs) between subtypes were identified to create a disulfidptosis prognostic model using LASSO and Cox regression analyses. This model was evaluated by comparing risk scores, survival curves, cellular infiltration, and drug sensitivity between high- and low-risk groups. Analyses revealed differential expression, mutations, and copy number variations (CNV) in DRGs in CRC. Survival analysis demonstrated significant prognostic differences among DRG expression subtypes. GSVA and ssGSEA highlighted DRGs' regulatory roles in CRC. DEGs identified between DRG expression subtypes led to the classification into subtypes A and B. A disulfidptosis prognostic model, including genes VSIG4, SCG2, INHBB, DDC, CXCL13, KLK10, CXCL10, and CCL11A, was developed to stratify patients into high- and low-risk groups. This model displayed strong predictive capability (AUC = 0.700) and calibration. The risk score was also strongly associated with immune cell infiltration, stromal cell score, and stem cell index in the CRC tumor microenvironment. Drug sensitivity analysis indicated that high-risk samples were more responsive to most medications. We established a robust disulfidptosis prognostic model for CRC through comprehensive multi-omics analysis. Our findings provide valuable insights into the role of DRGs in CRC progression and disease management, presenting an important resource for further research.
- Open Access
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1555601
Corrigendum: The role of fecal microbiota transplantation in type 2 diabetes mellitus treatment
In the published article, there was an error in the order of the figures as published. The content of the figures is correct, but the sequence was mistakenly arranged: Figure 3 should appear as Figure 1. Figure 1 should appear as Figure 2. Figure 2 should appear as Figure 3.
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1555601
Open AccessCorrigendum: The role of fecal microbiota transplantation in type 2 diabetes mellitus treatment
In the published article, there was an error in the order of the figures as published. The content of the figures is correct, but the sequence was mistakenly arranged: Figure 3 should appear as Figure 1. Figure 1 should appear as Figure 2. Figure 2 should appear as Figure 3.
- Open Access
- 13 December 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1469165
The role of fecal microbiota transplantation in type 2 diabetes mellitus treatment
In contemporary microbial research, the exploration of interactions between microorganisms and multicellular hosts constitutes a burgeoning field. The gut microbiota is increasingly acknowledged as a pivotal contributor to various disorders within the endocrine system, encompassing conditions such as diabetes and thyroid diseases. A surge in research activities has been witnessed in recent years, elucidating the intricate interplay between the gut microbiota and disorders of the endocrine system. Simultaneously, fecal microbiota transplantation (FMT) has emerged as a focal point, garnering substantial attention in both biomedical and clinical spheres. Research endeavors have uncovered the remarkable therapeutic efficacy of FMT across diverse diseases, with particular emphasis on its application in addressing type 2 diabetes mellitus (T2DM) and associated com-plications. Consequently, this manuscript accentuates the intimate connection between the gut microbiota and disorders within the endocrine system, with a specific focus on exploring the potential of FMT as an intervention in the therapeutic landscape of T2DM and its complications. Furthermore, the article scrutinizes concerns inherent in treatment modalities centered around the gut microbiota, proposing viable solutions to address these issues.
- 13 December 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1469165
Open AccessThe role of fecal microbiota transplantation in type 2 diabetes mellitus treatment
In contemporary microbial research, the exploration of interactions between microorganisms and multicellular hosts constitutes a burgeoning field. The gut microbiota is increasingly acknowledged as a pivotal contributor to various disorders within the endocrine system, encompassing conditions such as diabetes and thyroid diseases. A surge in research activities has been witnessed in recent years, elucidating the intricate interplay between the gut microbiota and disorders of the endocrine system. Simultaneously, fecal microbiota transplantation (FMT) has emerged as a focal point, garnering substantial attention in both biomedical and clinical spheres. Research endeavors have uncovered the remarkable therapeutic efficacy of FMT across diverse diseases, with particular emphasis on its application in addressing type 2 diabetes mellitus (T2DM) and associated com-plications. Consequently, this manuscript accentuates the intimate connection between the gut microbiota and disorders within the endocrine system, with a specific focus on exploring the potential of FMT as an intervention in the therapeutic landscape of T2DM and its complications. Furthermore, the article scrutinizes concerns inherent in treatment modalities centered around the gut microbiota, proposing viable solutions to address these issues.